The U.S. Food and Drug Administration on Tuesday released guidance for approving a coronavirus vaccine, saying the vaccine has to prevent or decrease disease severity in at least 50% of people who are inoculated.
Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
Gilead Sciences Inc said on Tuesday it would buy a 49.9% stake in privately held Pionyr Immunotherapeutics Inc for $275 million, strengthening its cancer portfolio by securing access to two promising drugs.
Quest Diagnostics Inc on Wednesday started offering blood tests, temperature monitoring and other tailored services to U.S. employers as they attempt to reopen factories and offices after months under coronavirus-led lockdowns.
Swiss drugmaker Roche Holding AG's Genentech unit said on Monday the U.S. Food and Drug Administration has approved Tecentriq as a standalone therapy for an advanced form of lung cancer.
Patients given the malaria drug touted by President Donald Trump as a potential treatment for COVID-19 did not improve significantly over those who did not, according to two new studies published in the medical journal BMJ on Thursday.
Hertz Global Holdings Inc on Monday raised going concern doubts as the car rental company tries to cut costs and avoid debt default amid a blow to its business due to the COVID-19 pandemic, sending its shares down 4% in extended trading.
The Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million to help develop and produce Novavax Inc's COVID-19 vaccine candidate, the company said on Monday, sending its shares up 31.2% in extended trading.
The U.S. Food and Drug Administration said on Friday it has authorized the first diagnostic test for the new coronavirus that allows patients to collect saliva samples at-home.
May 6 Novartis AG on Wednesday priced its treatment for a hard-to-treat form of lung cancer at the U.S. wholesale acquisition cost of $17,950 for a 28-day supply, following the drug's approval by regulators.
Hong Kong's national security law does not spell "doom and gloom", its leader said on Tuesday, as she tried to calm unease over legislation that critics say could quash freedoms that have underpinned the city's success as a financial hub.